Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).
Updates in Chronic Lymphocytic Leukemia from the ICML 2023 Meeting and Beyond
Subject-matter experts review treatment options for patients with relapsed/refractory CLL.
An insightful analysis of head-to-head trials comparing BTK inhibitors (acalabrutinib vs ibrutinib and zanubrutinib vs ibrutinib) to guide treatment selection in CLL.
Dr. Hill and Dr. Gia share how varying risk profiles of different BTK inhibitors may impact patient outcomes, along with relevant real-world data.
Exploring molecular mechanisms of resistance to BTK inhibitors as well as emergent data concerning how this resistance might be overcome.
Dr. Hill and Dr. Gia discuss treatment options for patients who progress on covalent and noncovalent BTK inhibitors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5